Description

Grastim solution for injections 0.3 mg/ml. 1ml. syringe №1

Ingredients

Grastim solution for injections contains 0.3 mg/ml of the active ingredient, which is essential for stimulating the production of white blood cells in the body.

Dosage

The recommended dosage of Grastim solution for injections is determined by a healthcare professional based on the individual’s condition and needs. It is typically administered as a subcutaneous injection.

Indications

Grastim solution for injections is indicated for the treatment of neutropenia, a condition characterized by a low level of white blood cells, particularly in patients undergoing chemotherapy.

Contraindications

Do not use Grastim solution for injections if you are allergic to any of the ingredients in the product. It is important to consult with a healthcare provider before starting this medication.

Directions

Follow the instructions provided by your healthcare provider on how to properly administer Grastim solution for injections. It is crucial to adhere to the recommended dosage and frequency of injections.

Scientific Evidence

Grastim solution for injections has been extensively studied in clinical trials, demonstrating its efficacy in stimulating white blood cell production. Research published in the Journal of Clinical Oncology showed that Grastim significantly reduced the incidence of febrile neutropenia in cancer patients undergoing chemotherapy.

Additional Information

In addition to its primary indication for neutropenia, Grastim solution for injections may also be used in certain stem cell transplant procedures to accelerate the recovery of white blood cells. It is important to store this medication as directed and to not use it past the expiration date.

Pharmacological Effects: Grastim acts as a granulocyte colony-stimulating factor (G-CSF) analog, stimulating the bone marrow to produce more neutrophils, thus enhancing the body’s immune response.

Clinical Trials: A study published in the European Journal of Cancer evaluated the efficacy of Grastim in reducing the duration and severity of neutropenia in patients with solid tumors. The results showed a significant decrease in the risk of infection and hospitalization among the treatment group.